Enveric Biosciences 3/25/2024 Earnings Report

Enveric Biosciences EPS Results

• Actual EPS: -$21.90
• Consensus EPS: -$23.25
• Beat/Miss: Beat by +$1.35
• One Year Ago EPS: N/A

Enveric Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Enveric Biosciences Announcement Details

• Date: 3/25/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Enveric Biosciences (NASDAQ:ENVB) is a clinical-stage biotechnology company focused on the discovery and development of first-in-class psychedelic-inspired therapeutics for oncology supportive care. The company’s research strategy centers on harnessing novel analogs of psychedelic compounds to address debilitating side effects of cancer treatments, including chemotherapy-induced peripheral neuropathy, cancer‐related fatigue, anxiety and post-traumatic stress disorder in oncology patients.

Enveric’s pipeline features proprietary molecules engineered for improved safety, tolerability and pharmacokinetic profiles compared with naturally occurring psychedelics. Its lead program, ENB-101, is a synthetic psilocybin analog in Phase 2 development for chemotherapy-induced peripheral neuropathy, while additional candidates are progressing toward clinical evaluation in cancer-related fatigue and anxiety. These programs are supported by preclinical data demonstrating neuroprotective and anti-inflammatory properties in relevant animal models.

Founded in 2019 and headquartered in Miami, Florida, Enveric maintains research and manufacturing operations in the United States and Europe. The company has initiated multiple clinical trials across North America and the European Union and collaborates with academic institutions, contract research organizations and patient advocacy groups to advance its oncology supportive care platform. Strategic partnerships aim to accelerate development timelines and expand access to its therapeutic candidates worldwide.

Enveric’s leadership team combines decades of experience in neuroscience, oncology drug development and pharmaceutical commercialization. The executive team and board of directors include veterans of leading biopharmaceutical companies who have guided programs through regulatory approval and global launches. Through its scientific advisory board, Enveric engages experts in neurology, oncology and psychedelic science to inform trial design and foster innovation across its therapeutic pipeline.